The $649 NGS test screens for 193 disorders, can be ordered online, and is designed to supplement standard state newborn screening services.
During the quarter, the company reopened its CLIA lab in New Haven, Connecticut, following the company's merger with Transgenomic in June.
The company also estimated full-year 2017 revenues to be between $23.7 million and $24.0 million, and announced a $15.8 million contract in Ethiopia.
Q-State Biosciences, which focuses on neurologic disorders, will work closely with WuXi NextCode to relaunch Claritas' exome assays.
Overall, revenues were up 8 percent. In the diagnostics segment, molecular product sales were driven primarily by continued strength across Aptima women's health products.
DiscernDx, which is backed by Khosla Ventures, stepped in to purchase API's assets after lender Square 1 Bank asserted a lien on the company late last year.
Launch Diagnostics will distribute BioGx's entire product line, including laboratory-use-only products, in the UK and Ireland.
The company's HIV testing revenues were up 24 percent year over year, while HCV testing revenues plummeted 68 percent.
The firm said it will use the net proceeds for R&D, including the continued development of its Acuitas AMR gene panels.
The firm reported total revenues of $194 million, compared to $196.5 million in Q2 2017, but beat the consensus Wall Street estimate of $188.8 million.
The PCR-based cartridge is designed to detect 21 pneumonia pathogens and 19 genetic markers of antibiotic resistance, and runs on the company's Unyvero system.
LabCorp Diagnostics revenues increased 9 percent in Q4, while Covance Drug Development grew revenues 24 percent.
The firm saw revenue growth across all segments, with diagnostic systems revenues increasing 14 percent.
AxonLab will distribute BioGx's entire product line, including laboratory-use-only products, in central European countries.
Angle aims to show that clinicians can determine HER-2 status by subjecting harvested circulating tumor cells to fluorescence in situ hybridization (FISH).
The company also announced that its Ares Genetics subsidiary has been awarded a €1.6 million grant to develop antibiotic resistance technologies.
The Nasdaq has told the firm that it is in compliance with all applicable listing standards and that its meeting with a hearings panel has been cancelled.
The firm is developing a rapid point-of-care diagnostic system focused on combating antimicrobial resistance.
The workflow was cleared by the South Korean Ministry of Food and Drug Safety for the typing of HLA-A, B, C, DRB1, and DQB1 by next-generation sequencing.
Leading the gainers in the 360 Index was GenMark, whose stock price was up 30 percent last month. Invitae led the decliners as its share price fell 24 percent.